Impact of the changes in the completion lymph node dissection criteria and approval of adjuvant therapies on the real-world outcomes of Japanese stage III melanoma patients.

Background: Completion lymph node dissection (CLND) has long been the standard treatment for stage III melanomas identified as metastasis on the sentinel node (SN-positive). Two major changes occurred in 2017 and 2018, the change in the CLND criteria for SN-positive patients and the approval of several adjuvant therapies could revolutionize such management approach. However, their effects have not been fully investigated on the real-world outcomes of stage III melanoma patients.

Systemic treatment of patients with advanced cutaneous squamous cell carcinoma: response rates and outcomes of the regimes used.

Background: Cutaneous squamous cell carcinoma (cSCC) is the second most common type of skin cancer. Few patients with cSCC experience metastases, but the prognosis of advanced cSCC (acSCC) is dismal. Evidence regarding systemic therapy for acSCC is limited.

Usefulness of sentinel lymph node biopsy for prognostic prediction in extramammary Paget's disease.

Complete excision of the primary lesion has long been considered the standard treatment for extramammary Paget's disease (EMPD). However, the presence of lymph node metastases has been reported as an important prognostic factor. We evaluated the association between lymph node metastasis and prognosis for EMPD using sentinel lymph node (SLN) biopsy.

[Sentinel node navigation surgery in melanoma and non-melanoma malignant skin tumor].

Sentinel node biopsy (SNB) has been performed for melanomas by many researchers since Morton's report in 1992. The technique has been well discussed, however, there have been only few reports about the application of SNB for treatment strategy of melanoma patients. Besides, we have not yet enough information of the clinical significance of SNB for non-melanoma malignant skin tumors.